Remove 2018 Remove Clinical Trials Remove Conditions Remove Safety
article thumbnail

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

The Cannigma

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinical trials tell us? Where can I buy CBN? Is it even legal?

THC 140
article thumbnail

Do you trust your doctor about cannabis?

The Cannigma

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. One of the more extensive reports of this nature was published in the Journal of Cannabis Research in 2018.

Education 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

article thumbnail

First Cannabis-Derived Rx Drug Now On The Market

Kind Meds (Cannabis Education Blog)

After securing FDA approval in June of 2018, Epidiolex’s manufacturer GW Pharma announced the drug should enter the consumer market by the end of 2018. Children who suffer from these conditions generally experience social and developmental delays due to constant seizures. Cannabis Legalization Throughout The Country.

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Beginning in 2018, the FDA has started to grant special designations to study the medicinal use of psilocybin via Breakthrough Therapy status. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.

Law 105
article thumbnail

A Patient’s Guide to CBD and Drug Interactions

Healer

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Based on my clinical experience, it is rare for people to experience CBD-drug interactions at doses below 100mg daily. .

CBD 98
article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. 1 Data published by Research and Markets, March 2018. Prior to joining MyMD and since 1999, Dr. Chapman has operated Chapman Pharmaceutical Consulting, Inc.,